Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite - 2Fire Allegedly Triggered by Wedding Cake Sparkler Causes Venue to Go Up in Flames, Leaving Groom with Second-Degree Burns
- 3America's Confided in Fridge in 2024
- 4Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- 5Why the Houthis waited until now to strike
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- Factbox-China's crewed lunar programme eyes astronaut landing by 2030
- Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
